

=> d his

(FILE 'HOME' ENTERED AT 14:35:51 ON 15 APR 2003)

FILE 'REGISTRY' ENTERED AT 14:36:00 ON 15 APR 2003

L1 STRUCTURE uploaded

L2 50 S L1

L3 2781 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:40:20 ON 15 APR 2003

S L1

FILE 'REGISTRY' ENTERED AT 14:40:25 ON 15 APR 2003

L4 50 S L1

FILE 'CAPLUS' ENTERED AT 14:40:26 ON 15 APR 2003


L5 31 S L4

L6 807 S L3

L7 5 S L6 AND (CEREBROVASCULAR DISORDER# OR CEREBRAL INFARCTION OR T

=> d que 17 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 2781 SEA FILE=REGISTRY SSS FUL L1

L6 807 SEA FILE=CAPLUS ABB=ON PLU=ON L3


L7 5 SEA FILE=CAPLUS ABB=ON PLU=ON L6 AND (CEREBROVASCULAR  
DISORDER# OR CEREBRAL INFARCTION OR TRANSIENT ISCHEMIC ATTACK  
OR TIA OR CEREBRAL APoplexy OR CEREBRAL HEMORRHAGE OR SUBARACHN  
OID HEMORRHAGE OR CRANIAL HEMORRHAGE OR CEREBROVASCULAR  
DEMENTIA OR HYPERTENSIVE ENCEPHALOPATHY)

=> d 1-5 ibib iabs hitstr

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002/755214 CAPLUS  
DOCUMENT NUMBER: 137-263024  
TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.  
INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, Jhon E.; Gu, Zhengxiang  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143024	A1	20021003	US 2000-737201	20001214
PRIORITY APPLN. INFO.:			US 1998-91847P	P 19980708
			US 1999-343592	B2 19990701
			US 1999-464037	B2 19991215
			US 2000-481197	B2 20000111
			US 2000-513779	A2 20000225
			US 2000-604322	B2 20000626
			US 2000-643640	B2 20000822

OTHER SOURCE(S): MARPAT 137:263024  
GRAPHIC IMAGE:



**ABSTRACT:** Title compds. (I: R1 = specified oxoimidazolyl, pyridotimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, (halo)alkyl,

ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



1-[2'-(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]2-ethyl-. 3-(2-oxo-1-pyrrolidinyl)propyl ester  
 254739-83-8P. 1H-Benzimidazole-7-carboxamide, 1-[2'-(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl-. 254739-84-9P. 1H-Benzimidazole-7-carboxamide,  
 1-[2'-(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N,N-dimethyl-. 254740-51-7P.  
 1H-Benzimidazole-7-carboxylic acid, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-. methyl ester 254740-52-8P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-2-ethyl-. methyl ester 254740-53-9P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-. methyl ester 254740-54-0P.  
 1H-Benzimidazole-7-carboxylic acid, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-  
 254740-55-1P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-. methyl ester 254740-56-2P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1-pyrrolidinyl)methyl-  
 254740-57-3P. 1H-Benzimidazole-7-carboxamide, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1-pyrrolidinyl)methyl-  
 254740-58-4P. 1H-Benzimidazole-7-carboxamide, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1-pyrrolidinyl)methyl-  
 254742-51-1P. 1H-Benzimidazole-7-carboxamide, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl-.  
 254742-53-5P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-. phenylmethyl ester 254742-54-6P.  
 1H-Benzimidazole-7-carboxylic acid, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-2-phenylmethyl ester 254742-56-8P. 1H-Benzimidazole-7-carboxylic acid, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-2-ethyl-  
 254742-58-0P. 1H-Benzimidazole-7-carboxylic acid,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-. (2-oxo-1-pyrrolidinyl)propyl ester  
 254742-67-1P. 1H-Benzimidazole-7-carboxamide, 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N-methyl-. 254742-68-2P. 1H-Benzimidazole-7-carboxamide,  
 1-[2'-(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-N,N-dimethyl-.  
 RUL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

Uses) (prepn. of N-isoazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)



L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO<sub>2</sub>, etc.;  
 R<sub>3</sub> = heteroaryl: R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl,  
 alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano,  
 OH, hydroxyalkyl, NO<sub>2</sub>, etc. (with provisos) were prep'd as dual angiotensin II  
 and endothelin receptor antagonists for treatment of hypertension and other  
 diseases (no data). Thus, 4-C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>OH was coupled with [2-[(4,5-dimethyl-3-  
 isoxazolyl)(2-[methoxyethoxy]methyl)amino]sulfonyl]phenyl]boronic acid to give  
 N-(4,5-dimethyl-1-3-isoxazolyl)-4-(hydroxymethyl)-N-[2-(  
 methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated  
 to give the 4'-bromomethyl deriv. (90%), reacted with 2-butyl-1,3-  
 diazepiro[4,4]non-1-en-4-one hydrochloride, and deprotected (49% for two  
 steps) to give 4'-(2-butyl-1-oxo-3,1-diazepiro[4,4]non-1-en-3-yl)methyl-N-  
 (4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

LN ANSWER 2-1  
RN 254738-13-1 CAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'·[[[3,4-dimethyl-5-  
isoxazolyl]amino]sulfonyl][1,1'-biphenyl-4-yl]methyl]-2-ethoxy-, methyl  
ester (SCI) (CA INDEX NAME)




RN 254738-14-2 CAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid. 1-[{2'-[{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}][1,1'-biphenyl]-4-yl}methyl]-2-ethoxy- (9CI)  
(CA INDEX NAME)




RN 254738-15-3 CAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid, 1-[(2'-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-1-methylester (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-16-4 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 254738-17-5 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


RN 254738-18-6 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




PAGE 1-A

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-19-7 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 1-A




RN 254738-20-0 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



PAGE 2-A

RN 254739-72-5 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 254739-73-6 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- phenylmethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



RN 254739-74-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-phenylethyl ester (9CI) (CA INDEX NAME)



RN 254739-75-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

RN 254739-76-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)


PAGE 2-A




RN 254739-76-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254739-83-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 254740-51-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)



RN 254740-52-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)


RN 254739-84-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 254740-53-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 1-[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- methyl  
 ester (9CI) (CA INDEX NAME)




RN 254740-54-0 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9CI) (CA  
 INDEX NAME)




RN 254740-55-1 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-  
 pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- methyl ester  
 (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-56-2 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-  
 pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA  
 INDEX NAME)




RN 254740-57-3 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-  
 pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI)  
 (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-58-4 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-  
 pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-  
 (9CI) (CA INDEX NAME)




RN 254742-51-3 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl-  
 (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-53-5 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- phenylmethyl ester (9CI) (CA INDEX NAME)




RN 254742-54-6 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 2-phenylethyl ester (9CI) (CA INDEX NAME)




RN 254742-56-8 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)


ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254742-58-0 CAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid, 1-[(2'-[[4-(5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl)methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 254742-67-1 CAPLUS  
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-(9CI) (CA INDEX NAME)




RN 254742-68-2 CAPLUS  
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methoxy]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




IT 254745-51-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[{[2'-[(3,4-dimethyl-1-isoxazolyl)[{[2-[(trimethylsilyloxy)ethoxy]methyl]amino]sulfonyl}oxy]biphenyl-4-yl]methyl]-2-ethoxy-, methyl ester  
 254745-58-9, 1H-Benzimidazole-7-carboxylic acid, 1-[{[2'-[(3,4-dimethyl-1-isoxazolyl)[{[2-[(trimethylsilyloxy)ethoxy]methyl]amino]sulfonyl}oxy]biphenyl-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]oxy]biphenyl-4-yl]methyl]-2-ethoxy-, methyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation): PREP (Preparation): RACT (Reactant or reagent)

RN 25475-51-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]2-[(trimethylsilyl)ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)

17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254745-58-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[(2-[(3,4-dimethyl-5-isoxyacetyl)oxyethoxy]methyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:551882

DOCUMENT NUMBER: 138:214720

**TITLE:** Potential for anti-cholinergic  
AT1-receptor blocker to reduce dementia in the elderly  
**AUTHOR(S):** Trenkwalder, P.  
**CORPORATE SOURCE:** Starnberg Hospital, Department of Internal Medicine,  
Ludwig Maximilian University Munich, Starnberg,  
Germany

SOURCE: Journal of Human Hypertension (2002). 16(Suppl. 3).  
571-575  
CODEN: JHHYEN; ISSN: 0950-9240  
PUBLISHER: Nature Publishing Group

PUBLISHER: *Journal of General Review*  
DOCUMENT TYPE: Journal: General Review  
LANGUAGE: English  
ISSUE DATE:

## ABSTRACT: A review: Hypertension is an established risk factor for stroke

## **\*\*\*cerebrovascular\*\*\*** disorder

## .....cerebral infarcts


and there is evidence that vascular risk factors play a major role in the development of both Alzheimer's disease and vascular dementia. Several large epidemiol. studies have shown that raised blood pressure in midlife is a strong risk factor for dementia later in life; however, blood pressure often decreases following the development of dementia. The cognitive function hypothesis proposes that elevated blood pressure increases the risk of decline of cognitive function, and that this can be reversed by active lowering of blood pressure. Evidence in support of this hypothesis comes from the Syst-Eur Dementia project, and from a no. of smaller studies. SCOPE (Study on Cognition and Prognosis in the Elderly) is a large prospective study involving almost 5000 elderly patients (age 70-89 yr), who are randomized to receive candesartan cilexetil, 8-16 mg, or placebo. Candesartan was chosen for this study because it is effective and well tolerated in elderly patients. SCOPE should provide important information on the long-term effects of AT1-receptor blocker treatment with candesartan on morbidity-including effects on cognitive function and cardiovascular mortality in elderly hypertensive patients.

IT 145040-37-5. Candesartan cilexetil  
RL: PAC (Pharmacological activity); THU (Therapeutic use); B10L  
(Biological study); USES (Uses)  
(potential for antihypertensive treatment with AT1-receptor blocker to  
reduce dementia in elderly humans)  
145040-37-5. Candesartan cilexetil

RN 145040-37-5 CAPLUS  
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[cyclohexyloxy]carbonyloxy]ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001453059 CAPLUS  
 DOCUMENT NUMBER: 135:46172  
 TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.  
 INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, John E.; Gu, Zhengxiang  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA  
 SOURCE: PCT Int. Appl., 287 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044239	A2	20010621	WO 2000-US33730	20001213
WO 2001044239	A3	20011101		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW. AH: AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GH, ML, MR, NE, SN, TD, TG EP 1237888				
EP 1237888 A2 20020911 EP 2000-984282 20001213				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 1999-464037 A 19991215 US 2000-481197 A 20000111 US 2000-513779 A 20000225 US 2000-604322 A 20000626 US 2000-643640 A 20000822 WO 2000-US33730 W 20001213				

OTHER SOURCE(S): MARPAT 135:46172  
 GRAPHIC IMAGE:

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




ABSTRACT:  
 Title compds. (I; R1 = specified oxoimidazolyl, pyridoimidazolyl, pyridylamino, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; with provisos) were prepd. as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[[4-dimethyl-3-isoxazolyl][(2-methoxyethoxy)methyl]amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl deriv. (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give II.


IT 254738-13-1P 254738-14-2P 254738-15-3P  
 254738-16-4P 254738-17-5P 254738-18-6P  
 254738-19-7P 254738-20-0P 254739-72-5P  
 254739-73-6P 254739-74-7P 254739-75-8P  
 254739-76-9P 254739-83-8P 254739-84-9P  
 254740-51-7P 254740-52-8P 254740-53-9P  
 254740-54-0P 254740-55-1P 254740-56-2P  
 254740-57-3P 254740-58-4P 254742-51-3P  
 254742-53-5P 254742-54-6P 254742-56-8P  
 254742-58-0P 254742-67-1P 254742-68-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); B10 (Biological study); PREP (Preparation); USES (Uses)  
 (prep. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254738-13-1 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-y]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-14-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-y]methyl]-2-ethoxy-, (9C1) (CA INDEX NAME)




RN 254738-15-3 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-y]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)



RN 254738-16-4 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 254738-17-5 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- . methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 254738-18-6 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




RN 254738-19-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A




PAGE 1-A

RN 254739-72-5 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9CI) (CA INDEX NAME)





RN 254738-20-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

RN 254739-73-6 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- . phenylmethyl ester (9CI) (CA INDEX NAME)




RN 254739-74-7 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-phenylethyl ester (9CI) (CA INDEX NAME)





RN 254739-75-8 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 254739-76-9 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 254739-83-8 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 254740-51-7 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254740-52-8 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254740-53-9 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-

CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-  
 isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl  
 ester (9CI) (CA INDEX NAME)




RN 254740-54-0 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 254740-55-1 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-56-2 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254740-57-3 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-58-4 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 254742-51-3 CAPLUS  
 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-53-5 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 254742-54-6 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester (9CI) (CA INDEX NAME)




RN 254742-56-8 CAPLUS  
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254742-58-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 254742-67-1 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 254742-68-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




IT 254745-51-2P 254745-58-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254745-51-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 254745-58-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)][2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:34745 CAPLUS  
 DOCUMENT NUMBER: 132:93309  
 TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.  
 INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, John E.; Gu, Zhengxiang  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA  
 SOURCE: PCT Int. Appl. 283 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001389	A1	20000113	WO 1999-US15063	19990701
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZM, AZ, BY, KG, KZ, AD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336714	AA	20000113	CA 1999-2336714	19990701
AU 9950888	A1	20000124	AU 1999-50888	19990701
EP 1094816	A1	20010502	EP 1999-935406	19990701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9911621	A	20011016	BR 1999-11621	19990701
EE 200100006	A	20020617	EE 2001-2001000619990701	
JP 2002519380	T2	20020702	JP 2000-557835	19990701
LT 4854	B	20011126	LT 2000-123	2001222
NO 2001000062	A	20010305	NO 2001-62	20010105
PRIORITY APPLN. INFO.:			US 1998-91847P	19980706
OTHER SOURCE(S): MARPAT 132:93309			WO 1999-US15063	W 19990701
GRAPHIC IMAGE:				



L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




**ABSTRACT:**  
 Title compds. (I; R1 = specified oximidazolyl, pyridoimidazolyl, pyridylamino, triazolyl, quinolinyloxy, etc.; R2 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteraryl; with provisos), were prep'd. as dual angiotensin II and endothelin receptor antagonists (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)(2-methoxyethoxy)methyl]amino]sulfonyl]phenoxy acid to give N-(4,5-dimethyl-3-isoxazolyl)-4-(hydroxymethyl)-N-(2-methoxyethoxy)phenyl]1,1'-biphenyl-2-sulfonamide. This was brominated to give 4'-bromomethyl-N-(4,5-dimethyl-3-isoxazolyl)-N-[(2-methoxyethoxy)methyl]1,1'-biphenyl-2-sulfonamide, which reacted with 2-buty-1,3-diazepro[4,4]non-1-en-4-one hydrochloride followed by deprotection to give 4'-[(2-buty-1,3-diazepro[4,4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-1,1'-biphenyl-2-sulfonamide.

IT 254738-13-1P 254738-14-2P 254738-15-3P  
 254738-16-4P 254738-17-5P 254738-18-6P  
 254738-19-7P 254738-20-0P 254739-72-5P  
 254739-73-6P 254739-74-7P 254739-75-8P  
 254739-76-9P 254739-83-8P 254739-84-9P  
 254740-51-7P 254740-52-8P 254740-53-9P  
 254740-54-0P 254740-55-1P 254740-56-2P  
 254740-57-3P 254740-58-4P 254742-51-3P  
 254742-53-5P 254742-54-6P 254742-56-8P  
 254742-58-0P 254742-67-1P 254742-68-2P  
 RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use): BIOL (Biological study); PREP (Preparation); USES (Uses) (prep. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254738-13-1 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 254738-14-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI)  
 (CA INDEX NAME)




RN 254738-15-3 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 254738-16-4 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254738-18-6 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)



RN 254738-17-5 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 1-A

RN 254738-19-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)





PAGE 2-A

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



PAGE 2-A

PAGE 1-A




RN 254739-72-5 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9CI) (CA INDEX NAME)

PAGE 2-A



RN 254738-20-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl]-2-[[3,3-dimethyl-1-pyrrolidinyl]methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 254739-73-6 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]-2-ethyl-phenylmethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



RN 254739-74-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-phenylethyl ester (9CI) (CA INDEX NAME)



PAGE 2-A




RN 254739-76-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)


RN 254739-75-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[3,4-dimethyl-5-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-83-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 254740-51-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- . methyl ester (9CI) (CA INDEX NAME)




RN 254740-52-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254739-84-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-53-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- . methyl ester (9CI) (CA INDEX NAME)




RN 254740-56-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254740-57-3 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 254740-54-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 254740-55-1 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- . methyl ester (9CI) (CA INDEX NAME)




RN 254740-58-4 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)





RN 254742-51-3 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 254742-58-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 254742-67-1 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 254742-53-5 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-phenylmethyl ester (9CI) (CA INDEX NAME)




RN 254742-54-6 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-2-phenylethyl ester (9CI) (CA INDEX NAME)




RN 254742-56-8 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-.

RN 254742-68-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




IT 254745-51-2P 254745-58-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation): RACT (Reactant or reagent)  
 (prepn. of N-isoxazolyl biphenylsulfonylamides and related compds. as dual angiotensin II and endothelin receptor antagonists)  
 RN 254745-51-2 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyloxy)ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- methyl ester (9CI) (CA INDEX NAME)



RN 254745-58-9 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[[2-[(trimethylsilyloxy)ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:811090 CAPLUS  
 DOCUMENT NUMBER: 132:30836  
 TITLE: Preventing cerebral infarction  
 through administration of ADP-receptor antiplatelet  
 and antihypertensive drugs in combination  
 INVENTOR(S): Melvin S. Caviglio, Anthony A.; Piat, Francis R.; Blumenthal, Melvin S.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 20 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965500	A1	19991223	WO 1999-US12934	19990609
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332608	AA	19991223	CA 1999-2332608	19990609
AU 994551	A1	20000105	AU 1999-45551	19990609
AU 750122	B2	20020711		
EP 1087775	A1	20010404	EP 1999-928498	19990609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6248729	B1	20010619	US 1999-328812	19990609
PRIORITY APPLN. INFO.: US 1998-89650P			US 1998-89650P	P 19980617
WO 1999-US12934	W		WO 1999-US12934	W 19990609

ABSTRACT:  
 A method is provided for preventing a cerebral infarction by administering to a patient a combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, in combination with an antihypertensive agent such as an angiotensin AI antagonist (for example, losartan), an ACE inhibitor (for example, fosinopril) or a NEP/ACE inhibitor such as omapatrilat.

IT 139481-59-7. Candesartan 144701-48-4. Telmisartan  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preventing cerebral infarction through

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 administration of ADP-receptor antiplatelet and antihypertensive drugs  
 in combination)RN 139481-59-7 CAPLUS  
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1,4'-dimethyl-2'-propyl)[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (losartan or eprosartan or candesartan (w) cilexetil or candesartan or valsartan or telmisartan or  
irbesartan or olmesartan or tasosartan)/cn

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'NDESARTAN (W) CILEXETIL'

1 LOSARTAN/CN  
1 EPROSARTAN/CN  
1 CANDESARTAN/CN  
0 CILEXETIL/CN  
1 CANDESARTAN/CN  
1 VALSARTAN/CN  
1 TELMISARTAN/CN  
1 IRBESARTAN/CN  
1 OLMESARTAN/CN  
1 TASOSARTAN/CN

L8 8 (LOSARTAN OR EPROSARTAN OR CANDESARTAN (W) CILEXETIL OR CANDESARTAN OR VALSARTAN OR TELMISARTAN OR IRBESARTAN OR OLMESARTAN OR TASOSARTAN)/CN

=> s (candesartan cilexetil)/cn  
L9 1 (CANDESARTAN CILEXETIL)/CN

=> s 18 or 19  
L10 9 L8 OR L9

## L10 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 145733-36-4 REGISTRY  
 CN Pyrido[2,3-d]pyrimidin-7(6H)-one, 5,8-dihydro-2,4-dimethyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Tasosartan

CN WAY-ANA 756

FS 3D CONCORD

DR 153042-16-1

MF C23 H21 N7 O

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MRCK\*, MSDS-OHS, PHAR, PRMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(\*file contains numerically searchable property data)

Other Sources: WHO

## L10 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 137:358120

REFERENCE 5: 137:288447


REFERENCE 6: 137:253025

REFERENCE 7: 137:145599

REFERENCE 8: 137:114551

REFERENCE 9: 137:11000

REFERENCE 10: 136:406900



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

58 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 59 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:215317

REFERENCE 2: 138:180405

REFERENCE 3: 137:380012

## L10 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 145040-37-5 REGISTRY  
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl] ester (9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl] ester, (.\*-).

## OTHER NAMES:

CN (.\*-)-1-Hydroxyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)]-7-benzimidazolcarboxylate, cyclohexyl carbonate (ester)

CN Atacand

CN Candesartan cilexetil

CN TCV 116

CN TCY 116

FS 3D CONCORD

DR 139481-74-6, 198077-85-9

MF C33 H34 N6 O6

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNS, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, MSDS-OHS, PHAR, PRMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2.

USPATFULL

(\*file contains numerically searchable property data)

Other Sources: WHO

## L10 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

340 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 340 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:231500

REFERENCE 2: 138:214720

REFERENCE 3: 138:210444

REFERENCE 4: 138:163223

REFERENCE 5: 138:158871

REFERENCE 6: 138:147508


REFERENCE 7: 138:147482

REFERENCE 8: 138:147418


REFERENCE 9: 138:66247

REFERENCE 10: 138:61310

PAGE 1-A



L10 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS  
 RN 144701-48-4 REGISTRY  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[{(1,4'-dimethyl-2'-propyl)[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 4'-[{(4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl)-1-benzimidazolyl)methyl]-2-biphenylcarboxylic acid  
 CN BIBR 277  
 CN BIBR 277SE  
 CN Micardis  
 CN Prior  
 CN Telmisartan  
 FS 3D CONCORD  
 MF C33 H31 N4 O2  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNS, CHEMCATS, CHEMIFORMIX, CHEMIST, CIN, CSHEM, DDFU, DIOPHES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, SYNTHLINE, TOX CENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

156 REFERENCES IN FILE CA (1962 TO DATE)  
 157 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:226765

L10 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2003 ACS  
 RN 144689-24-7 REGISTRY  
 CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Olmesartan  
 CN RINH 6270  
 FS 3D CONCORD  
 MF C24 H26 N6 O3  
 SR CA  
 LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, DRUGPAT, DRUGUPDATES, IPA, PROMT, TOX CENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


21 REFERENCES IN FILE CA (1962 TO DATE)  
 21 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:226765  
 REFERENCE 2: 138:158871  
 REFERENCE 3: 138:130974  
 REFERENCE 4: 138:130810  
 REFERENCE 5: 137:358176  
 REFERENCE 6: 137:304828  
 REFERENCE 7: 137:11015  
 REFERENCE 8: 137:440  
 REFERENCE 9: 136:128768  
 REFERENCE 10: 135:338594

L10 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 2: 138:215317  
 REFERENCE 3: 138:198540  
 REFERENCE 4: 138:163224  
 REFERENCE 5: 138:158871  
 REFERENCE 6: 138:130848  
 REFERENCE 7: 138:100631  
 REFERENCE 8: 138:82835  
 REFERENCE 9: 138:44556  
 REFERENCE 10: 138:19309

L10 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS  
 RN 139481-59-7 REGISTRY  
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid  
 CN Candesartan  
 CN Candesartan M1  
 CN CV 11974  
 FS 3D CONCORD  
 MF C24 H20 N6 O3  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNS, CHEMCATS, CHEMIFORMIX, CHEMIST, CIN, DIOPHES, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PROMT, TOX CENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

327 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 330 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 138:243276  
 REFERENCE 2: 138:236216  
 REFERENCE 3: 138:226765  
 REFERENCE 4: 138:215317  
 REFERENCE 5: 138:214718  
 REFERENCE 6: 138:214716  
 REFERENCE 7: 138:214715  
 REFERENCE 8: 138:214714

548/352

L10 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)  
REFERENCE 9: 138:214713

REFERENCE 10: 138:198384

L10 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS  
RN 138402-11-6 REGISTRY  
CN 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyi-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2-Butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one  
CN Aprovel  
CN Avapro  
CN BMS 186295  
CN Irbesartan  
CN Karvea  
CN SR 47436  
FS 3D CONCORD  
MF C25 H28 N6 O  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHECMATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PRMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

362 REFERENCES IN FILE CA (1962 TO DATE)  
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
364 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243276

REFERENCE 2: 138:231534

REFERENCE 3: 138:231507

L10 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)  
REFERENCE 4: 138:226765

REFERENCE 5: 138:215317

REFERENCE 6: 138:214768

REFERENCE 7: 138:214713


REFERENCE 8: 138:198354

REFERENCE 9: 138:175664

REFERENCE 10: 138:162849

L10 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS  
RN 137862-53-4 REGISTRY  
CN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN CGP 48933  
CN Diovan  
CN Nisis  
CN Tareg  
CN Valsartan  
FS STEREOSEARCH  
DR 186597-74-0  
MF C24 H29 N5 O3  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOPHARMA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHECMATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PRMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

368 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
372 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243276

REFERENCE 2: 138:231535

REFERENCE 3: 138:226765

L10 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 138:226705

REFERENCE 5: 138:215702

REFERENCE 6: 138:215317

REFERENCE 7: 138:214713

REFERENCE 8: 138:158871

REFERENCE 9: 138:130789

REFERENCE 10: 138:89813

L10 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 133040-01-4 REGISTRY

CN 2-Thiophenepropanoic acid, .alpha.-[[2-buty-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene]-, (.alpha;E)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Thiophenepropanoic acid, .alpha.-[[2-buty-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl)methylene]-, (E)-

OTHER NAMES:

CN (E)-2-Butyl-1-(p-carboxybenzyl)-.alpha.-2-thienylimidazole-5-acrylic acid

CN Eprosartan

CN SKB 108566

CN SKF 108566

FS STEREOSEARCH

MF C23 H24 N2 O4 S


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMINFORMRX, CIN, DIOPGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL (\*File contains numerically searchable property data)

Other Sources: WHO

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

200 REFERENCES IN FILE CA (1962 TO DATE)

201 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:215317

REFERENCE 2: 138:158871

REFERENCE 3: 138:100632

L10 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 138:100631

REFERENCE 5: 138:83116

REFERENCE 6: 138:213

REFERENCE 7: 137:380012

REFERENCE 8: 137:358176

REFERENCE 9: 137:358120

REFERENCE 10: 137:257397

L10 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 114798-26-4 REGISTRY  
CN 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN DUP 89

CN Lortaan

CN Losartan

FS 3D CONCORD


MF C22 H23 Cl N6 O

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSHEM, DDFU, DIOPGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, MRCK\*, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL (\*File contains numerically searchable property data)

Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1456 REFERENCES IN FILE CA (1962 TO DATE)

15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1459 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243419

REFERENCE 2: 138:243276

REFERENCE 3: 138:235485

REFERENCE 4: 138:231516

REFERENCE 5: 138:231504

REFERENCE 6: 138:226854

REFERENCE 7: 138:226765

REFERENCE 8: 138:226705


L10 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 9: 138:215317

REFERENCE 10: 138:215254

1997:405439 Document No. 127:39817 Pharmaceutical compositions containing imidazopyridines as **angiotensin II** antagonists.  
 Sekine, Yasuo; Kawanishi, Eiki; Narita, Hiroshi; Hashimoto, Yoshihiro; Mizobe, Masakazu (Tanabe Seiyaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 09110691 A2 19970428 Heisei, 7 pp. (Japanese). CODEN: JKXXAF.  
 APPLICATION: JP 1995-267560 19951017.

GI



AB Pharmaceutical compns.. useful for treatment and/or prevention of hypertension, nephritis, diabetic nephritis, primary aldosteronemia, atherosclerosis, dementia, cerebral circulation disorder, chronic heart failure, and angina pectoris. contain imidazopyridines I (R1, R3, R4 = lower alkyl; R2 = lower alkanoyl; R3R4 may form C3-6 alkylene) or their pharmacol. acceptable salts as active ingredients. I are easily absorbed by digestive tract and converted into active forms. I (R1 = Pr, R2 = Ac, R3 = R4 = Et) HCl salt (II) at 0.3 mg/kg i.d. suppressed 61.6% angiotensin II-induced hypertension in dogs. LD50 of II

1996:319527 Document No. 125:25882 ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats. Nagura, Jun; Hui, Chen; Yamamoto, Mikio; Yasuda, Sumie; Abe, Mitsuhiro; Hachisu, Mitsugu; Konno, Fukio (Pharmaceutical Res. Center, Meiji Seika Kaisha, Ltd., Yokohama, 222, Japan). Japanese Journal of Pharmacology, 71(1), 39-49 (English) 1996. CODEN: JJPAAZ. ISSN: 0021-5198. Publisher: Japanese Pharmacological Society.

AB The protective effects of ME3221, 3-methoxy-2,6-dimethyl-4-[(2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methoxy]pyridine, on aged (32-wk-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 mo) oral administration. At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications obsd. in control SHRSP: **cerebral apoplexy** (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl- $\beta$ -D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion. The protective activity of ME3221, a surmountable angiotensin AT1-receptor antagonist, was comparable to losartan, an insurmountable AT1-antagonist, and also to enalapril, an angiotensin-converting enzyme inhibitor. In addn. ME3221 reduced the systolic blood pressure more effectively than the two ref. drugs.

1993:462704 Document No. 119:62704 Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. Stier, Charles T., Jr.; Adler, Lawrence A.; Levine, Seymour; Chander, Praveen N. (Dep. Pharmacol., New York Med. Coll., Valhalla, NY, 10595, USA). Journal of Hypertension. 11(3), S37-S42 (English) 1993. CODEN: JOHYD3. ISSN: 0263-6352.

AB Treatment with the **angiotensin II** antagonist losartan at 30 mg/kg/day, orally, delayed the development of severe hypertension and prevented stroke in saline-drinking stroke-prone spontaneously hypertensive rats (SHRSP); doses of 10 mg/kg/day did not affect the hypertension but prevented the occurrence of **cerebrovascular** lesions until age  $\geq$  28 wk. These and other data are consistent with the theory that **angiotensin II** has an effect on the pathophysiol. of **cerebrovascular** lesion development in saline-drinking SHRSP and that losartan protects against such development in the absence of a blood pressure fall.